Tectonic Therapeutic, Inc. (TECX) stock
TECXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$21.14+0.10 (+0.48%)
Close on Nov 13, 2026Market cap $413.27MP/E –Yield 0.00%
Tectonic Therapeutic operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Tectonic Therapeutic's operating cash flow for the twelve months ending Sep 30, 2026 was -$69.23M. For fiscal 2025 it was -$60.08M. The highest annual figure on record is -$16.38M in fiscal 2017.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$60.08M | – |
| FY2024 | Dec 31, 2024 | -$59.08M | – |
| FY2023 | Dec 31, 2023 | -$40.68M | – |
| FY2022 | Dec 31, 2022 | -$97.21M | – |
| FY2021 | Dec 31, 2021 | -$98.03M | – |
| FY2020 | Dec 31, 2020 | -$98.80M | – |
| FY2019 | Dec 31, 2019 | -$67.67M | – |
| FY2018 | Dec 31, 2018 | -$37.65M | – |
| FY2017 | Dec 31, 2017 | -$16.38M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$14.91M | – |
| Q2 FY2026 | Jun 30, 2026 | -$21.45M | – |
| Q1 FY2026 | Mar 31, 2026 | -$18.41M | – |
| Q4 FY2025 | Dec 31, 2025 | -$14.46M | – |
| Q3 FY2025 | Sep 30, 2025 | -$17.82M | – |
| Q2 FY2025 | Jun 30, 2025 | -$14.72M | – |
| Q1 FY2025 | Mar 31, 2025 | -$13.08M | – |
| Q4 FY2024 | Dec 31, 2024 | -$16.82M | – |
| Q3 FY2024 | Sep 30, 2024 | -$19.60M | – |
| Q2 FY2024 | Jun 30, 2024 | -$13.38M | – |
| Q1 FY2024 | Mar 31, 2024 | -$9.27M | – |
| Q4 FY2023 | Dec 31, 2023 | -$11.66M | – |
| Q3 FY2023 | Sep 30, 2023 | -$8.48M | – |
| Q2 FY2023 | Jun 30, 2023 | -$259.00K | – |
| Q1 FY2023 | Mar 31, 2023 | -$20.28M | – |
| Q4 FY2022 | Dec 31, 2022 | -$23.67M | – |
| Q3 FY2022 | Sep 30, 2022 | -$16.42M | – |
| Q2 FY2022 | Jun 30, 2022 | -$29.11M | – |
| Q1 FY2022 | Mar 31, 2022 | -$28.01M | – |
| Q4 FY2021 | Dec 31, 2021 | -$25.90M | – |
| Q3 FY2021 | Sep 30, 2021 | -$24.82M | – |
| Q2 FY2021 | Jun 30, 2021 | -$19.97M | – |
| Q1 FY2021 | Mar 31, 2021 | -$27.34M | – |
| Q4 FY2020 | Dec 31, 2020 | -$30.49M | – |
| Q3 FY2020 | Sep 30, 2020 | -$24.86M | – |
| Q2 FY2020 | Jun 30, 2020 | -$21.02M | – |
| Q1 FY2020 | Mar 31, 2020 | -$22.43M | – |
| Q4 FY2019 | Dec 31, 2019 | -$18.58M | – |
| Q3 FY2019 | Sep 30, 2019 | -$13.38M | – |
| Q2 FY2019 | Jun 30, 2019 | -$17.97M | – |
| Q1 FY2019 | Mar 31, 2019 | -$17.74M | – |
| Q4 FY2018 | Dec 31, 2018 | -$11.43M | – |
| Q3 FY2018 | Sep 30, 2018 | -$11.99M | – |
| Q2 FY2018 | Jun 30, 2018 | -$8.25M | – |
| Q1 FY2018 | Mar 31, 2018 | -$5.98M | – |
| Q4 FY2017 | Dec 31, 2017 | -$8.83M | – |
| Q3 FY2017 | Sep 30, 2017 | -$3.10M | – |
See a number that looks wrong?